Press Release Archive
Press Releases
March 2024
03.20.2024 Financial Finance Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts 03.13.2024 Vaccines Vaccines European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease 03.12.2024 Medicines Research Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) 03.05.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 2024
02.29.2024 Financial Investments Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth 02.29.2024 Vaccines Vaccines Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults 02.26.2024 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 02.19.2024 Prescription Medicines Medicines European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis 02.15.2024 Financial Finance Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day 02.12.2024 Corporate Partnerships UT Southwestern collaborates with Pfizer to develop improved RNA Delivery Technologies 02.05.2024 Prescription Medicines Responsibility Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
January 2024
01.30.2024 Corporate Financial Finance Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.